Letrozole
Breast cancer drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Letrozole?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Letrozole, sold under the brand name Femara among others, is an aromatase inhibitor medication that is used in the treatment of breast cancer.[1]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Femara, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a698004 |
License data | |
Routes of administration | By mouth |
Drug class | Aromatase inhibitor; Antiestrogen |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 99.9% |
Protein binding | 60%, mainly to albumin |
Metabolism | pharmacologically-inactive metabolites Bis(4-cyanophenyl)methanol and 4,4'-dicyanobenzophenone.[3] |
Elimination half-life | 2 days[3] |
Excretion | Kidney[3] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.200.357 |
Chemical and physical data | |
Formula | C17H11N5 |
Molar mass | 285.310 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Close
It was patented in 1986 and approved for medical use in 1996.[4] In 2021, it was the 222nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.[5][6] It is on the World Health Organization's List of Essential Medicines.[7]